Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma.
Cytology
KRAS
Pancreatic ductal adenocarcinoma
Peritoneal washing fluid
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
received:
17
04
2024
accepted:
09
09
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
Positive peritoneal washing cytology is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC); however, its sensitivity is relatively low. This study evaluated the performance of peptide nucleic acid (PNA)-directed PCR clamping as a molecular-based peritoneal washing cytology for sensitive detection of KRAS mutation in PDAC. Intraoperative peritoneal washing fluid (IPWF) obtained from patients with PDAC who underwent surgery was analyzed. PNA-directed PCR clamping was performed on DNA extracted from IPWF. Among 54 patients enrolled, threshold cycle (Ct) was significantly lower in patients with positive peritoneal washing cytology than in those with negative peritoneal washing cytology (P < 0.001) and in patients with peritoneal dissemination than in those without peritoneal dissemination (P < 0.01). The optimal Ct cut-off to predict KRAS mutations in IPWF was 36.42 based on a receiver operating characteristic curve. The sensitivity, specificity, and accuracy for molecular diagnosis were 100%, 80.0%, and 85.2%, respectively. Peritoneal dissemination recurrence was significantly more frequent in patients with a positive molecular diagnosis than in those with a negative diagnosis (38.9 vs. 8.0%, P = 0.013). The genomic approach might be clinically valuable for a more precise tumor cell detection in IPWF.
Identifiants
pubmed: 39289461
doi: 10.1038/s41598-024-72569-8
pii: 10.1038/s41598-024-72569-8
doi:
Substances chimiques
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
KRAS protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21732Informations de copyright
© 2024. The Author(s).
Références
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 71(1), 7–33. https://doi.org/10.3322/caac.21654 (2021).
doi: 10.3322/caac.21654
pubmed: 33433946
Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74(11), 2913–2921. https://doi.org/10.1158/0008-5472.CAN-14-0155 (2014).
doi: 10.1158/0008-5472.CAN-14-0155
pubmed: 24840647
Tanaka, M. et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br. J. Surg. 106(12), 1590–1601. https://doi.org/10.1002/bjs.11295 (2019).
doi: 10.1002/bjs.11295
pubmed: 31454073
Tsuchida, H. et al. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan pancreas society. Surgery 166(6), 997–1003. https://doi.org/10.1016/j.surg.2019.06.023 (2019).
doi: 10.1016/j.surg.2019.06.023
pubmed: 31445763
Shimane, G. et al. Preoperative predictive factors for positive peritoneal cytology results in patients with pancreatic ductal adenocarcinomas: A retrospective study. Int. J. Clin. Oncol. 29(7), 985–993. https://doi.org/10.1007/s10147-024-02523-1 (2024).
doi: 10.1007/s10147-024-02523-1
pubmed: 38598039
Yonkus, J. A. et al. Molecular peritoneal staging for pancreatic ductal adenocarcinoma using mutant KRAS droplet-digital polymerase chain reaction: Results of a prospective clinical trial. J. Am. Coll. Surg. 233(1), 73-80.e1. https://doi.org/10.1016/j.jamcollsurg.2021.05.009 (2021).
doi: 10.1016/j.jamcollsurg.2021.05.009
pubmed: 34022414
Suenaga, M. et al. Peritoneal lavage tumor DNA as a novel biomarker for predicting peritoneal recurrence in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 28, 2277–2286. https://doi.org/10.1245/s10434-020-08990-w (2020).
doi: 10.1245/s10434-020-08990-w
pubmed: 32875467
Chiba, K. et al. Impact of tumor-derived DNA testing in peritoneal lavage of pancreatic cancer patients with and without occult intra-abdominal metastases. Ann. Surg. Oncol. 29(4), 2685–2697. https://doi.org/10.1245/s10434-021-10997-w (2022).
doi: 10.1245/s10434-021-10997-w
pubmed: 34739641
Nakano, Y. et al. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: A retrospective study. Br. J. Cancer 118(5), 662–669. https://doi.org/10.1038/bjc.2017.479 (2018).
doi: 10.1038/bjc.2017.479
pubmed: 29360815
pmcid: 5846073
Hayashi, H. et al. Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology 18(6), 647–654. https://doi.org/10.1016/j.pan.2018.07.006 (2018).
doi: 10.1016/j.pan.2018.07.006
pubmed: 30055942
Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32(2), 185-203.e13. https://doi.org/10.1016/j.ccell.2017.07.007 (2017).
doi: 10.1016/j.ccell.2017.07.007
Yokose, T. et al. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer. Cancer Sci. 111(6), 2174–2182. https://doi.org/10.1111/cas.14425 (2020).
doi: 10.1111/cas.14425
pubmed: 32314446
pmcid: 7293095
Nakamura, Y. & Shitara, K. Development of circulating tumour DNA analysis for gastrointestinal cancers. ESMO Open https://doi.org/10.1136/esmoopen-2019-000600 (2020).
doi: 10.1136/esmoopen-2019-000600
pubmed: 32830648
pmcid: 7381840
Taback, B. et al. Peptide nucleic acid clamp PCR: A novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. Int. J. Cancer 111(3), 409–414. https://doi.org/10.1002/ijc.20268 (2004).
doi: 10.1002/ijc.20268
pubmed: 15221969
Kim, J. et al. Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut 55(11), 1598–1605. https://doi.org/10.1136/gut.2005.083063 (2006).
doi: 10.1136/gut.2005.083063
pubmed: 16682430
pmcid: 1860104
Shinozaki, M. et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin. Cancer Res. 13(7), 2068–2074. https://doi.org/10.1158/1078-0432.CCR-06-2120 (2007).
doi: 10.1158/1078-0432.CCR-06-2120
pubmed: 17404088
pmcid: 2720029
Kitago, M. et al. Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. Int. J. Cancer 110(2), 177–182. https://doi.org/10.1002/ijc.20084 (2004).
doi: 10.1002/ijc.20084
pubmed: 15069678
Kim, I. et al. Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non-small cell lung cancer patients. Thorac. Cancer 10(7), 1561–1566. https://doi.org/10.1111/1759-7714.13101 (2019).
doi: 10.1111/1759-7714.13101
pubmed: 31148357
pmcid: 6610248
Deveson, I. W. et al. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat. Biotechnol. 39(9), 1115–1128. https://doi.org/10.1038/s41587-021-00857-z (2021).
doi: 10.1038/s41587-021-00857-z
pubmed: 33846644
pmcid: 8434938
Li, B. T. et al. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: Results from the actionable genome consortium. Ann. Oncol. 30(4), 597–603. https://doi.org/10.1093/annonc/mdz046 (2019).
doi: 10.1093/annonc/mdz046
pubmed: 30891595
pmcid: 6503621
Ariake, K. et al. Preceding systemic chemotherapy for patients with pancreatic ductal adenocarcinoma with positive peritoneal cytology provides survival benefit compared with up-front surgery. Ann. Surg. Oncol. 28(11), 6246–6254. https://doi.org/10.1245/s10434-021-09718-0 (2021).
doi: 10.1245/s10434-021-09718-0
pubmed: 33611747
Kagawa, Y. et al. Combined analysis of concordance between liquid and tumor tissue biopsies for RAS mutations in colorectal cancer with a single metastasis site: The METABEAM study. Clin. Cancer Res. 27(9), 2515–2522. https://doi.org/10.1158/1078-0432.CCR-20-3677 (2021).
doi: 10.1158/1078-0432.CCR-20-3677
pubmed: 33602686
Igarashi, T. et al. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology. Annal. Gastroenterol. Surg. 00, 1–9. https://doi.org/10.1002/ags3.12719 (2023).
doi: 10.1002/ags3.12719
Endo, Y., Kitago, M. & Kitagawa, Y. Evidence and future perspectives for neoadjuvant therapy for Resectable and borderline Resectable pancreatic cancer: A scoping review. Cancers (Basel) 16(9), 1632. https://doi.org/10.3390/cancers16091632 (2014).
doi: 10.3390/cancers16091632
Kitago, M. et al. Adjuvant 5-fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer. Cancer Med. 13(14), e7459. https://doi.org/10.1002/cam4.7459 (2024).
doi: 10.1002/cam4.7459
pubmed: 39030993
pmcid: 11258433
Nakano, Y. et al. Next-generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Oncol. Lett. 27(4), 139. https://doi.org/10.3892/ol.2024.14272 (2024).
doi: 10.3892/ol.2024.14272
pubmed: 38385113
pmcid: 10877230
Corcoran, R. B. & Chabner, B. A. Application of cell-free DNA analysis to cancer treatment. N. Engl. J. Med. 379(18), 1754–1765. https://doi.org/10.1056/NEJMra1706174 (2018).
doi: 10.1056/NEJMra1706174
pubmed: 30380390
Nakamura, Y. et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat. Med. 26(12), 1859–1864. https://doi.org/10.1038/s41591-020-1063-5 (2020).
doi: 10.1038/s41591-020-1063-5
pubmed: 33020649
Petiti, J. et al. Highly sensitive detection of IDH2 mutations in acute myeloid leukemia. J. Clin. Med. 9(1), 271. https://doi.org/10.3390/jcm9010271 (2020).
doi: 10.3390/jcm9010271
pubmed: 31963812
pmcid: 7019902
Shu, Y. et al. Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci. Rep. 7(1), 583. https://doi.org/10.1038/s41598-017-00520-1 (2017).
doi: 10.1038/s41598-017-00520-1
pubmed: 28373672
pmcid: 5428730
Fujita, Y. et al. Pathogenesis of multiple pancreatic cancers involves multicentric carcinogenesis and intrapancreatic metastasis. Cancer Sci. 111(2), 739–748. https://doi.org/10.1111/cas.14268 (2020).
doi: 10.1111/cas.14268
pubmed: 31799787
pmcid: 7004534
Wan, J. C. M. et al. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17(4), 223–238. https://doi.org/10.1038/nrc.2017.7 (2017).
doi: 10.1038/nrc.2017.7
pubmed: 28233803
Kuo, Y. B., Chen, J. S., Fan, C. W., Li, Y. S. & Chan, E. C. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. Clin. Chim. Acta 433, 284–289. https://doi.org/10.1016/j.cca.2014.03.024 (2014).
doi: 10.1016/j.cca.2014.03.024
pubmed: 24685572
Mayo-de-Las-Casas, C. et al. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof-of-concept study. Int. J. Cancer 147(1), 277–284. https://doi.org/10.1002/ijc.32872 (2020).
doi: 10.1002/ijc.32872
pubmed: 31953839
Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531(7592), 47–52. https://doi.org/10.1038/nature16965 (2016).
doi: 10.1038/nature16965
pubmed: 26909576
Bae, G. E., Kim, S. H., Choi, M. K., Kim, J. M. & Yeo, M. K. Targeted sequencing of ascites and peritoneal washing fluid of patients with gastrointestinal cancers and their clinical applications and limitations. Front Oncol. https://doi.org/10.3389/fonc.2021.712754 (2021).
doi: 10.3389/fonc.2021.712754
pubmed: 34804985
pmcid: 8595921
Nakamura, K. et al. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status. Med. Oncol. 38(4), 36. https://doi.org/10.1007/s12032-021-01482-1 (2021).
doi: 10.1007/s12032-021-01482-1
pubmed: 33710417
pmcid: 7954749